BridgeMD
Lidocaine in Liver Surgery
EU CTIS ID: 2023-508173-90-00
What this study is testing
To evaluate the efficiency of intravenously administered Lidocaine in minor hepatectomy patients
- Phase II and Phase III (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥ 18 years.
- Patients planned for minor hepatectomy in Lund.
- Informed consent in writing.
You likely can't join if
- ASA score >3
- Class 3 antiarythmis (such as cordarone)
- Ongoing treatment with opioids.
- Uncapable, unwilling or language difficulties making patient unable to understand scope of study
- concomittant drugs: Erythromycin, clarithromycin, Fluvoxamine, Cimetidine, antiviral-HIV-medication and imidazol-drugs.
- Chirrosis
See the full eligibility criteria
- Age ≥ 18 years.
- Patients planned for minor hepatectomy in Lund.
- Informed consent in writing.
- ASA score >3
- Class 3 antiarythmis (such as cordarone)
- Ongoing treatment with opioids.
- Uncapable, unwilling or language difficulties making patient unable to understand scope of study
- concomittant drugs: Erythromycin, clarithromycin, Fluvoxamine, Cimetidine, antiviral-HIV-medication and imidazol-drugs.
- Chirrosis
- Preoperative decreased liverfunction, defined as ASAT/ALAT/bilirubin above twice the upper normal limit
- Pregnancy
- AV- block >1 without pacemaker
- WHO class >2.
- Allergy to lidocaine or other local anaesthesia
- Heart failure
- Epilepsy
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.